Cencora, Inc. $COR Shares Purchased by AE Wealth Management LLC

AE Wealth Management LLC increased its stake in Cencora, Inc. (NYSE:COR) by 12.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,320 shares of the company’s stock after purchasing an additional 2,528 shares during the period. AE Wealth Management LLC’s holdings in Cencora were worth $7,289,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of COR. Janney Montgomery Scott LLC raised its holdings in shares of Cencora by 4.7% in the second quarter. Janney Montgomery Scott LLC now owns 45,984 shares of the company’s stock worth $13,789,000 after buying an additional 2,058 shares during the last quarter. Capital Investment Advisors LLC raised its stake in Cencora by 9.7% in the 2nd quarter. Capital Investment Advisors LLC now owns 1,050 shares of the company’s stock worth $315,000 after acquiring an additional 93 shares during the last quarter. Cooper Financial Group acquired a new stake in Cencora during the 2nd quarter worth about $302,000. Robeco Institutional Asset Management B.V. grew its stake in Cencora by 232.1% during the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 178,345 shares of the company’s stock valued at $53,477,000 after purchasing an additional 124,639 shares during the last quarter. Finally, J. Safra Sarasin Holding AG grew its stake in Cencora by 420.2% during the 2nd quarter. J. Safra Sarasin Holding AG now owns 56,023 shares of the company’s stock valued at $16,798,000 after purchasing an additional 45,254 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insider Activity

In related news, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total value of $1,868,397.44. Following the sale, the chief executive officer owned 65,746 shares of the company’s stock, valued at approximately $24,105,113.44. This trade represents a 7.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the company’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the transaction, the executive vice president owned 23,891 shares of the company’s stock, valued at $8,173,111.10. This represents a 12.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 20,316 shares of company stock worth $7,151,265 in the last quarter. Corporate insiders own 0.38% of the company’s stock.

Analyst Ratings Changes

COR has been the subject of several research analyst reports. Bank of America reduced their price objective on Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a research note on Monday, January 5th. TD Cowen raised their price target on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Barclays assumed coverage on shares of Cencora in a research note on Monday, December 8th. They set an “overweight” rating and a $400.00 price objective for the company. Mizuho increased their price objective on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Finally, Robert W. Baird set a $415.00 target price on shares of Cencora in a research report on Tuesday, January 13th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $393.08.

Cencora Stock Up 2.0%

COR opened at $359.14 on Friday. The company has a fifty day moving average of $347.62 and a two-hundred day moving average of $323.87. The stock has a market capitalization of $69.67 billion, a price-to-earnings ratio of 45.17, a PEG ratio of 1.68 and a beta of 0.66. Cencora, Inc. has a fifty-two week low of $237.71 and a fifty-two week high of $377.54. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.05. The firm had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. Cencora had a return on equity of 227.15% and a net margin of 0.48%.Cencora’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio is currently 30.19%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.